![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in
Description
We concluded her liver decompensation was most likely secondary to semaglutide-induced rapid weight loss and malnutrition
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-025-03774-9/MediaObjects/41591_2025_3774_Fig1_HTML.png)
Foundayo Weight Loss Pill: What to Know About Orforglipron in 2026 Share Foundayo Weight Loss Pill: What to Know About Orforglipron in 2026 What if you could get the benefits of GLP-1 weight loss medication but without having to prick yourself every week
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.fbsbx.com/lookaside/crawler/threads/DJje2DSoYna/0/image.jpg)
About 89 percent of White respondents have heard of GLP-1s, compared to 69 percent of Black respondents and 74 percent of Hispanic respondents
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3867649560772410799)
Choose clinicians who will titrate slowly, communicate openly, and build a plan thats as committed to de-prescribing as it is to prescribing
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://www.2minutemedicine.com/wp-content/uploads/2025/05/2MM_VA_14may2025.jpg)
Both treatments offer distinct benefits, making them suitable for different preferences and health goals
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://pbs.twimg.com/media/FyRDpLdagAAVXYI.png)
